Pfizer Inc. (PFE) Presents Phase 3 Safety and Immunogenicity Data on Prevnar 13® in Adults With HIV  
3/5/2013 9:54:18 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])in adults infected with human immunodeficiency virus (HIV). The results were presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, Ga.